Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
AI holds the promise of improving gerontology by making it more predictive, personalized, preventive and participatory. However, to get there, an equal number of pronounced risks must be negotiated.
Patient-facing healthcare workers are neither softened nor hardened in their attitudes toward clinical decision support powered by AI when it’s instead called “AHI,” for augmented human intelligence.
An AI system trained to supply clinical decision support in the U.S. has proven adaptable for physicians treating patients with lung cancer on the other side of the globe.
The vast majority of patients with suspected melanoma—94%—would welcome the use of AI as an augmenter of their dermatologist’s diagnostic skills. And more than 40% would trust their diagnosis to a standalone AI system.
Cross-Atlantic researchers have developed two AI models that are fast and accurate at screening for COVID-19, offering hospitals potential options when lab testing is backed up or unavailable.
Asked to identify which of six fictional persons is most likely to be a terrorist, 85% of 1,500 participants in a psychology experiment selected one of the least likely suspects. And they did so specifically because they’d seen an AI robot make the ridiculous choice first.
Researchers have used AI-powered risk prediction to accurately screen the entire inpatient population of a community hospital for sepsis, enabling early treatment of the stricken.
Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.
The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals.
As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”
